Papers of the Week

Atopic dermatitis is the most common chronic dermatitis in the developed countries and is characterized by a low Quality of Life because of continuous/relapsing itching and difficulty to sleep. While dupilumab is, at present, the first choice or severe cases that are a minor percentage of cases, the majority of patients use topical products to relieve their symptoms. Even though topical corticosteroids are the more effective treatment for acute flares, their use should be limited in time to avoid the possible side-effects. Oral probiotics, to date, have not given robust evidence of efficacy against atopic dermatitis and topical probiotics are not allowed by regulatory agencies. So prebiotics and postbiotics are under investigations. This trial has confirmed that a cosmeceutic cream (Rilastil Xerolact PB) containing a mixture of prebiotics and postbiotics is effective in reducing the signs and symptoms of atopic dermatitis. In addition, as far it concerns the scales of itch, more than 80% of patients prefer PRURISCORE compared to classic VAS scale.